Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cannabinoids and multiple sclerosis.

Roger G Pertwee1

  • 1Department of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Scotland, UK. rgp@aberdeen.ac.uk

Pharmacology & Therapeutics
|August 17, 2002
PubMed
Summary

Cannabis and cannabinoids show promise for relieving multiple sclerosis and spinal cord injury symptoms like spasticity and pain. Further research is needed to confirm efficacy and optimize cannabinoid treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

A Tourette Syndrome/ADHD-like Phenotype Results from Postnatal Disruption of CB<sub>1</sub> and CB<sub>2</sub> Receptor Signalling.

International journal of molecular sciences·2025
Same author

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.

British journal of pharmacology·2023
Same author

The Plant Derived 3-3'-Diindolylmethane (DIM) Behaves as CB<sub>2</sub> Receptor Agonist in Prostate Cancer Cellular Models.

International journal of molecular sciences·2023
Same author

M3 Receptor Pathway Stimulates Rapid Transcription of the CB1 Receptor Activation through Calcium Signalling and the CNR1 Gene Promoter.

International journal of molecular sciences·2023
Same author

Pharmacological evaluation of enantiomerically separated positive allosteric modulators of cannabinoid 1 receptor, GAT591 and GAT593.

Frontiers in pharmacology·2022

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Growing evidence suggests cannabis and cannabinoids can alleviate symptoms in multiple sclerosis (MS) and spinal cord injury (SCI).
  • Anecdotal reports and small clinical trials indicate potential benefits for spasticity, pain, tremor, and nocturia.

Purpose of the Study:

  • To review the clinical and experimental evidence for cannabinoid efficacy in MS and SCI.
  • To explore the mechanisms underlying cannabinoid effects in these conditions.
  • To identify future research directions for cannabinoid-based therapies.

Main Methods:

  • Review of clinical trials involving cannabis, Delta(9)-tetrahydrocannabinol, and nabilone in MS and SCI patients.
  • Analysis of animal model experiments, specifically using mice with chronic relapsing experimental allergic encephalomyelitis (CREAE).
  • Investigation of cannabinoid receptor (CB(1) and CB(2)) involvement and endocannabinoid system modulation.

Main Results:

  • Clinical trials demonstrated objective and/or subjective improvements in spasticity, pain, tremor, and nocturia.
  • Animal studies provided strong evidence that cannabinoid receptors mediate reductions in tremor and spasticity.
  • Elevated endocannabinoid concentrations in affected areas of CREAE mice suggest a role for the endocannabinoid system.

Conclusions:

  • Cannabinoids show therapeutic potential for managing MS and SCI symptoms, particularly spasticity and pain.
  • Cannabinoid receptors and the endocannabinoid system are key mediators of these therapeutic effects.
  • Further research is essential to confirm efficacy, optimize administration, and separate therapeutic from adverse effects.

Related Experiment Videos